Skip To Content
Get Our Newsletter
JEWISH. INDEPENDENT. NONPROFIT.

Support the Forward

Funded by readers like you DonateSubscribe
News

One in Six US Drugs Will Soon Be Made in Israel

JERUSALEM (JTA) – Israel-based Teva Pharmaceutical Industries has completed its $40 billion purchase of the generic medicine division of Allergan, its chief competitor.

As part of the deal completed on Tuesday, Allergan received $33.4 billion in cash and 100.3 million shares of Teva stock.

Allergan’s Anda Inc is the 4th-largest distributor of generic pharmaceuticals in the U.S. Anda distributes generic, brand, specialty and over-the-counter pharmaceutical products from more than 300 manufacturers to pharmacies, nursing homes, hospitals, clinics and physician offices across the United States.

Teva is the world’s largest manufacturer of generic drugs. Anda will continue to operate as a standalone division, Teva said in a statement issued Tuesday.

Teva CEO Erez Vigodman said Tuesday in an interview with the French news agency AFP that the acquisition is part of a wider plan to become one of the “most competitive, fully integrated companies in the industry.”

He told AFP that, in the wake of the deal, “one in six prescriptions in the U.S. (will be) Teva, one in six in the U.K., one in eight in Germany.” He denied that the acquisition would lead to higher generic drug prices.

The sale is subject to anti-trust clearance. Teva reportedly will have to sell off 79 of its pharmaceutical products in order to come into compliance.

Engage

  • SHARE YOUR FEEDBACK

  • UPCOMING EVENT

    NY-12 Candidate Forum

    THE TEMPLE EMANU-EL STREICKER CENTER and Virtual

    Aug 10, 2022

    7 pm ET · 

    Will the last Jew left in New York’s congressional delegation be reelected? Will New York’s senior congresswoman receive another term? Or will one of the newcomers upend Manhattan politics?

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free under an Attribution-Non Commercial-No Derivatives Creative Commons license as long as you follow our republishing guidelines, which require that you credit Foward and retain our pixel. See our full guidelines for more information.

To republish, copy the HTML, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline, and credit to Foward. Have questions? Please email us at help@forward.com.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.